Clinical Trial DRUG STML-701-0114
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- Principal Investigator
- Jeffrey Raizer
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG STML-701-0114
- The goal of this research study is to establish the safety and tolerability of the drug SL-701, and to determine its effects on patients with recurrent Glioblastoma Multiforme (GBM) tumors.
- SL-701 is an experimental medication. This means that the United States Food and Drug Administration (FDA) has not yet approved SL-701. SL-701 is an anti-cancer immunotherapy that uses 3 different short proteins, called “peptides,” that are found in certain brain tumors. The immunotherapy is designed to activate the immune system to recognize and kill brain-tumor cells that display proteins similar to the peptides in SL-701.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have tumor recurrence (cancer came back) or progression (cancer is worsening)after initial (first) treatment.
- Participants who received prior cancer chemotherapy with bevacizumab or other VEGF-VEGFR-directed agents (check with the study doctor for any exclusions) cannot participate in this study.
- Description of Treatment
- Participants will receive SL-701 as an injection (shot by needle) along with an additional medication that will make the immune response stronger. This additional medication (poly-ICLC) is referred to as an adjuvant. Participants will also receive bevacizumab (approved by the FDA for the treatment of GBM) in combination with SL-701 and poly-ICLC. To receive study treatment, participants will come to the study center two times per week for the first 2 weeks, every week for the next 2 weeks, and every 2 weeks thereafter through Week 22. After Week 22, participants will come to the clinic every 4 weeks to receive SL-701 and poly-ICLC injections. Bevacizumab will continue to be given every 2 weeks after Week 22.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
- A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- Phase I/II trial of Radiation Therapy plus Temozolomide with MK-3475 in patients with newly diagnosed Glioblastoma (GBM)
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
last updated: 08-Oct-15 03:07 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.